BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 34121327)

  • 1. Evaluation of population-level pharmacogenetic actionability in Alabama.
    Davis BH; Williams K; Absher D; Korf B; Limdi NA
    Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing Clinical Utility of Pharmacogenetic Testing in the Military Health System.
    Hellwig LD; Turner C; Olsen C; Libbus J; Markos B; Koehlmoos T; Haigney M; De Castro M; Saunders D
    Mil Med; 2024 Jan; 189(1-2):e198-e204. PubMed ID: 37436924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
    Verma SS; Keat K; Li B; Hoffecker G; Risman M; ; Sangkuhl K; Whirl-Carrillo M; Dudek S; Verma A; Klein TE; Ritchie MD; Tuteja S
    J Transl Med; 2022 Nov; 20(1):550. PubMed ID: 36443877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
    Ramsey LB; Ong HH; Schildcrout JS; Shi Y; Tang LA; Hicks JK; El Rouby N; Cavallari LH; Tuteja S; Aquilante CL; Beitelshees AL; Lemkin DL; Blake KV; Williams H; Cimino JJ; Davis BH; Limdi NA; Empey PE; Horvat CM; Kao DP; Lipori GP; Rosenman MB; Skaar TC; Teal E; Winterstein AG; Owusu Obeng A; Salyakina D; Gupta A; Gruber J; McCafferty-Fernandez J; Bishop JR; Rivers Z; Benner A; Tamraz B; Long-Boyle J; Peterson JF; Van Driest SL;
    JAMA Netw Open; 2020 Dec; 3(12):e2029411. PubMed ID: 33315113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital.
    Roberts TA; Wagner JA; Sandritter T; Black BT; Gaedigk A; Stancil SL
    Clin Transl Sci; 2021 Jan; 14(1):412-421. PubMed ID: 33048453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada.
    Fan M; Yarema MC; Box A; Hume S; Aitchison KJ; Bousman CA
    Pharmacogenet Genomics; 2021 Feb; 31(2):29-39. PubMed ID: 32826605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetal pharmacogenomics: A promising addition to complex neonatal care.
    Raymond M; Critchlow E; Rice SM; Wodoslawsky S; Berger SI; Hegde M; Empey PE; Al-Kouatly HB
    Mol Genet Metab; 2022; 137(1-2):140-145. PubMed ID: 36029725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
    Dong OM; Li A; Suzuki O; Oni-Orisan A; Gonzalez R; Stouffer GA; Lee CR; Wiltshire T
    Pharmacogenomics; 2018 Jun; 19(9):771-782. PubMed ID: 29793377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.
    Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL
    J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines.
    Pritchard D; Patel JN; Stephens LE; McLeod HL
    Am J Health Syst Pharm; 2022 Jun; 79(12):993-1005. PubMed ID: 35230418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription Patterns and Relationship to Pharmacogenomics Testing in the Military Health System.
    Selig DJ; Livezey JR; Chin GC; DeLuca JP; Guillory Ii WO; Kress AT; Oliver TO; Por ED
    Mil Med; 2021 Dec; 187(Suppl 1):9-17. PubMed ID: 34967405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease.
    Elchynski AL; Cicali EJ; Ferrer Del Busto MC; Hamilton A; Chang KL; Schmidt SO; Weiner B; Davis R; Estores D; Max Smith D; Wiisanen K; Johnson JA; Cavallari LH
    Pharmacogenomics J; 2021 Dec; 21(6):657-663. PubMed ID: 34075203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities for Pharmacogenetic Testing to Guide Dosing of Medications in Youths With Medicaid.
    Tang Girdwood S; Hall M; Antoon JW; Kyler KE; Williams DJ; Shah SS; Orth LE; Goldman J; Feinstein JA; Ramsey LB
    JAMA Netw Open; 2024 Feb; 7(2):e2355707. PubMed ID: 38349656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
    Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
    Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
    Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
    Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of targeted vs. expanded pharmacogenomic testing: What are we missing?
    Chambal M; Forsthoffer C; Egnaczyk A; Seitz M; Grande K; Ashcraft K; Wick JA; Blaxall BC
    J Am Pharm Assoc (2003); 2023; 63(3):939-945. PubMed ID: 37024375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
    van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Care Prescription Drug Use and Related Actionable Drug-Gene Interactions in the Danish Population.
    Lunenburg CATC; Hauser AS; Ishtiak-Ahmed K; Gasse C
    Clin Transl Sci; 2020 Jul; 13(4):798-806. PubMed ID: 32166845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.